Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome

American Journal of Cardiology

Volumn 81, Issue 4 A, 1998, Pages 18B-25B

  Grundy, Scott M ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ATHEROGENESIS; CONFERENCE PAPER; CORONARY ARTERY DISEASE; CORONARY RISK; GLUCOSE INTOLERANCE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; METABOLIC DISORDER; PRIORITY JOURNAL; SYNDROME; THROMBOSIS;

EID: 0032567996     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(98)00033-2     Document Type: Conference Paper

References (65)

1. Austin MA. Plasma triglyceride and coronary artery disease. Arterioscler Thromb 1991;11:2-14.
2. Hokanson JE, Austin MA. Plasma triglyceride level as a risk factor for cardiovascular disease independent of high-density lipoprotein level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996;3:213-219.
3. Austin MA, King M-C, Vranizan KM, Krauss RM. Atherogenic lipoprotein phenotype: a proposed genetic marker for coronary artery disease risk. Circulation 1990;82:495-506.
4. Austin MA, Breslow JL, Hennekens CH, Buring JE, Willett KC, Krauss RM. Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 1988;260:1917-1921.
5. Grundy SM. Small LDL, atherogenic dyslipidemia, and the metabolic syndrome. Circulation 1997;95:1-4.
6. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 1993;269:3015-3023.
7. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Grundy SM, chairman). National Cholesterol Education Program: second report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol (Adult Treatment Panel II). Circulation 1994;89:1329-1445.
8. Strong JP. Atherosclerosis in primates: introduction and overview. Primates Med 1976;9:1-15.
9. Goldstein JL, Brown MS. Familial hypercholesterolemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease. New York: McGraw-Hill, 1995;1981-2030.
10. Castelli WP, Garrison RJ, Wilson PWF, Abbott RD, Kalousdain S, Kannel WB. Incidence of coronary artery disease and lipoprotein cholesterol levels: the Framingham Study. JAMA 1986;256:2835-2838.
11. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary artery disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389.
12. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, McKillop JH, Packard CJ, for the West of Scotland Coronary Prevention Study Group. Prevention of coronary artery disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-1307.
13. Sacks FM, Pfeffer MA, Moye LA, Rouleau JE, Rutherford JD, Cole triglyceride, Brown L, Warnica JW, Arnold JMO, Wun C-C, Davis BR, Braunwald E, for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-1009.
14. Mahley RW, Rail SC Jr. Type III hypolipoproteinemia (dysbetalipoproteinemia): the role of apolipoprotein E in normal and abnormal lipoprotein metabolism. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease. New York: McGraw-Hill, 1995;1953-1980.
15. Mahley RW. Atherogenic hyperlipoproteinemia: the cellular and molecular biology of plasma lipoproteins altered by dietary fat and cholesterol. Med Clin North Am 1982;66:375-402.
16. Nakashima Y, Plump AS, Raines EW, Breslow JE, Ross R. ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler Thromb 1994;14:133-140.
17. Minnich A, Zilversmit DB. Impaired triacylglycerol catabolism in hypertriglyceridemia of the diabetic, cholesterol-fed rabbit: a possible mechanism for protection from atherosclerosis. Biochim Biophys Acta 1989;1002:324-332.
18. Brunzell JD. Familial lipoprotein lipase deficiency and other causes of the chylomicronemia syndrome. In: Scriver CR, Beaudet AL, Sly WS, Varlee D, eds. The Metabolic and Molecular Bases of Inherited Disease. New York: McGraw-Hill, 1995;1913-1932.
19. Brunzell JD, Schrott HG, Motulsky AG, Bierman EL. Myocardial infarction in familial forms of hypertriglyceridemia. Metabolism 1976;25:313-320.
20. Brunzell JD, Albers JJ, Chait A, Grundy SM, Groszek E, McDonald GB. Plasma lipoproteins in familial combined hyperlipidemia and monogenic familial hypertriglyceridemia. J Lipid Res 1983;24:147-155.
21. Hulley SB, Rosenman RH, Bawol RD, Brand RJ. Epidemiology as a guide to clinical decisions: the association between triglyceride and coronary artery disease. N Engl J Med 1980;302:1383-1389.
22. Report from the Committee of Principal Investigators. A cooperative trial in the primary prevention of ischaemic heart disease using clofibrate. Br Heart J 1978;40:1069-1103.
23. Frick MH, Elo MO, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitanieni P, Koskinen P, Manninen V, Maenpaa H, Malkonen M, Manttari M, Norola S, Paternack A, Pikkarainen J, Romo M, Sjoblom T, Nikkila EA. Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med 1987;317:1237-1245.
24. Ericcson C-G, Hamsten A, Nilsson J, Grip L, Svane B, deFaire U. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet 1996;347:849-853.
25. Grundy SM, Vega GL. Fibric acids: Effects on lipids and lipoprotein metabolism. Am J Med 1987;83:9-20.
26. Canner PL, Berge KG, Wenger NK, for the Coronary Drug Project Research Group. Fifteen year mortality in coronary drug project patients: long-term benefit with niacin. J Am Coll Cardiol 1986;8:1245-1255.
27. Carlson LA, Rosenhamer G. Reduction of mortality in the Stockholm ischaemic heart disease secondary prevention study to combined treatment with clofibrate and nicotinic acid. Acta Med Scand 1988;223:405-418.
28. Vega GL, Grundy SM. Does measurement of apolipoprotein B have a place in cholesterol management? Arteriosclerosis 1990;10:668-671.
29. Abate N, Vega GL, Grundy SM. Variability in cholesterol content and physical properties of lipoproteins containing apolipoprotein B-100. Atherosclerosis 1993;104:159-171.
30. Sniderman AD, Wolfson C, Teng B, Franklin FA, Bachorik PS, Kwiterovich PO, Jr. Association of hyperapobetalipoproteinemia with endogenous hypertriglyceridemia and atherosclerosis. Ann Intern Med 1982;97:833-839.
31. Fager G, Wiklund O, Olofsson SO, Wilhelmsen L, Bondjers G. Multivariate analyses of serum apolipoproteins and risk factors in relation to acute myocardial infarction. Arteriosclerosis 1981;1:273-279.
32. Gordon DJ, Probstfeld JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, Jacobs DR, Jr, Bangdiwala S, Tyroler HA. High-density lipoprotein cholesterol and cardiovascular disease: four prospective American series. Circulation 1989; 79:8-15.
33. Frost PH, Davis BR, Burlando A, Curb JD, Guthrie GP Jr, Issacsohn JL, Wassertheil-Smoller, Wilson AC, Stamler J, for the Systolic Hypertension in the Elderly Research Program. Serum lipids and incidence of coronary artery disease: findings from the Systolic Hypertension in the Elderly Program (SHEP). Circulation 1996;94:2381-2388.
34. Vega GL, Grundy SM. Management of primary mixed hyperlipidemia with lovastatin. Arch Intern Med 1990;150:1313-1319.
35. Garg A, Grundy SM. Lovastatin for lowering cholesterol levels in non-insulin-dependent diabetes mellitus. N Engl J Med 1988;318:81-86.
36. Mostaza JM, Schulz I, Vega GL, Grundy SM. Comparison of pravastatin with crystalline nicotinic acid monotherapy in treatment of combined hyperlipidemia. Am J Cardiol 1997;79:1298-1301.
37. Garg A, Grundy SM. Management of dyslipidemia in NIDDM. Diabetes Care 1990;13:153-169.
38. Richards EG, Grundy SM, Cooper K. Influence of plasma triglycerides on lipoprotein patterns in normal subjects and in patients with coronary artery disease. Am J Cardiol 1989;63:1214-1220.
39. Schaefer EJ, Levy RI, Anderson DW, Dannu RN, Brewer HB. Plasma triglycerides in regulation of HDL-cholesterol. Lancet 1978;2:391-393.
40. Blades B, Vega GL, Grundy SM. Activities of lipoprotein lipase and hepatic triglyceride lipase in postheparin plasma of patients with low concentrations of HDL cholesterol. Arterioscler Thromb 1993;13:1227-1235.
41. Zambon A, Austin MA, Brown BG, Hokanson JE, Brunzell JD. Effect of hepatic lipase on LDL in normal men and those with coronary artery disease. Arterioscler Thromb 1993;13:147-153.
42. Kuusi T, Ehnholm C, Viikari J, Harkonen R, Vartiainen E, Puska P, Taskinen M-R. Post-heparin plasma lipoprotein and hepatic lipase are determinants of hypo- and hyper-alphalipoproteinemia. J Lipid Res 1989;30:1117-1126.
43. Vega GL, Grundy SM. Two patterns of LDL metabolism in normotriglyceridemic patients with hypoalphalipoproteinemia. Arterioscler Thromb 1993;13: 579-589.
44. Grundy SM, Vega GL. Two different views of the relationship of hypertriglyceridemia to coronary artery disease: implications for treatment. Arch Intern Med 1992;152:28-34.
45. Austin MA, Hokanson JE, Brunzell JD. Characterization of low-density lipoprotein subclasses: methodologic approaches and clinical relevance. Curr Opin Lipidol 1994;5:395-403.
46. Lamarche B, Tchernof A, Moorjani S, Cantin B, Dagenais GR, Lupien PJ, Despres JP. Small, dense low density lipoprotein phenotype as a predictor of the risk of ischemic heart disease in men: prospective results from the Quebec Cardiovascular Study. Circulation 1997;95:69-75.
47. de Graaf J, Hak-Lemmers HLM, Hectors PNM, Demacker JCM, Stalenholf AFH. Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfractions in healthy subjects. Arterioscler Thromb 1991;11:298-306.
48. Miller GJ, Miller NE. Plasma high density lipoprotein concentration and development of ischaemic heart disease. Lancet 1975;i:16-19.
49. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary artery disease: the Framingham Study. Am J Med 1977;62:707-714.
50. Breslow JL. Familial disorders of high density lipoproteins. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease. New York: McGraw-Hill. 1989:2031-2052.
51. Plump AS, Scott CJ, Breslow JL. Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in apolipoprotein E-deficient mouse. Proc Natl Acad Sci USA 1994;91:9607-9611.
52. Vega GL, Grundy SM. Gemfibrozil therapy in primary hypertriglyceridemia associated with coronary artery disease: effects on metabolism of low-density lipoproteins. JAMA 1985;253:2398-2403.
53. East C, Bilheimer DW, Grundy SM. Combination drug therapy for familial combined hyperlipidemia. Ann Intern Med 1988;109:25-32.
54. Reaven GM. Insulin resistance and its consequences: non-insulin dependent diabetes mellitus and coronary artery disease. In: LeRoith D, Taylor SL, Olefsky JM, eds. Diabetes Mellitus Philadelphia: Lippincott-Raven Publishers, 1996: 509-519.
55. Mostaza JM, Vega GL, Snell P, Grundy SM. Abnormal metabolism of free fatty acids in hypertriglyceridemic man: apparent insulin resistance of adipose tissue. J Intern Med 1997 (in press).
56. Kissebah AH, Alfarsi S, Adams PW, Wynn V. Role of insulin resistance in adipose tissue and liver in the pathogenesis of endogenous hypertriglyceridemia in man. Diabetalogia 1976;12:563-571.
57. Bruce R, Godsland I, Walton C, Crook D, Wynn V. Associations between insulin sensitivity and free fatty acid and triglyceride metabolism independent of uncomplicated obesity. Metabolism 1994;43:1275-1281.
58. Maruhama Y, Ohneda A, Tadaki H, Ohtsuki M, Yanbe A, Abe R, Yamagata S. Hepatic steatosis and the elevated plasma insulin level in patients with endogenous hypertriglyceridemia. Metabolism 1975;24:653-664.
59. Randle PJ, Priestman DA, Mistry S, Halsall A. Mechanisms modifying glucose oxidation in diabetes mellitus. Diabetologia 1994;37:S155-S161.
60. Lee Y, Hirose H, Ohneda M, Johnson JH, McGarry JD, Unger RH. Beta-cell lipotoxicity in the pathogenesis of non-insulin-dependent diabetes mellitus of obese rats: impairment in adipocyte-beta cell relationships. Proc Natl Acad Sci USA 1994;91:10878-10882.
61. Bierman EL. Atherogenesis in diabetes: George Lyman Duff memorial lecture. Arterioscler Thromb 1992;12:647-656.
62. Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities - the role of insulin resistance and the sympathoadrenal system. N Engl J Med 1996;334:374-381.
63. Pollare T, Lithell H, Berne C. Insulin resistance is a characteristic feature of primary hypertension independent of obesity. Metabolism 1990;39:167-174.
64. Juhan-Vague I, Alessi MC, Vague P. Increased plasma plasminogen activator inhibitor 1 levels: a possible link between insulin resistance and atherothrombosis. Diabetologia 1991;34:457.
65. Juhan-Vague I, Thompson SG, Jespersen J, on behalf of the ECAT Angina Pectoris Study Group. Involvement of the hemostatic system in the insulin resistance syndrome. (Abstr.) Arterioscler Thromb 1993;13: 1865.